It seems that no one with money will sponsor a program of ours until we prove it is efficacious in humans. I have said many times that we need a pre-clinical deal, but I am afraid that seems less likely than ever because, no matter how much good pre-clinical data we produce, the share price stays in the doldrums.
Let's hope that either the CoH or the Calimmune results go some way to convincing pharma that ddRNAi works and has a place in the treatment of human indications. Roll on August.
BLT Price at posting:
14.0¢ Sentiment: None Disclosure: Held